ZA963714B - Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours. - Google Patents

Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours.

Info

Publication number
ZA963714B
ZA963714B ZA9603714A ZA963714A ZA963714B ZA 963714 B ZA963714 B ZA 963714B ZA 9603714 A ZA9603714 A ZA 9603714A ZA 963714 A ZA963714 A ZA 963714A ZA 963714 B ZA963714 B ZA 963714B
Authority
ZA
South Africa
Prior art keywords
hours
active ingredient
parathyroid hormone
administration form
release period
Prior art date
Application number
ZA9603714A
Other languages
English (en)
Inventor
Peter-Paul Ochlich
Bernd Mueller-Beckmann
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of ZA963714B publication Critical patent/ZA963714B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA9603714A 1995-05-12 1996-05-10 Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours. ZA963714B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19517430A DE19517430A1 (de) 1995-05-12 1995-05-12 Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode

Publications (1)

Publication Number Publication Date
ZA963714B true ZA963714B (en) 1997-11-10

Family

ID=7761731

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9603714A ZA963714B (en) 1995-05-12 1996-05-10 Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours.

Country Status (7)

Country Link
EP (1) EP0825872A1 (xx)
JP (1) JPH11505222A (xx)
AU (1) AU5816596A (xx)
DE (1) DE19517430A1 (xx)
IL (1) IL118202A0 (xx)
WO (1) WO1996035447A1 (xx)
ZA (1) ZA963714B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CN101355959B (zh) 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
ME02474B (me) 2010-05-12 2017-02-20 Radius Health Inc Terapijski režimi
BR112013007685B1 (pt) 2010-09-28 2021-11-09 Radius Pharmaceuticals, Inc Compostos moduladores de receptor andrógeno seletivos, composição farmacêutica compreendendo os referidos compostos, método de identificação de um composto capaz de modular um receptor andrógeno, usos de um composto ou da composição e processo para a preparação de um composto
IL297369B1 (en) 2015-04-29 2024-02-01 Radius Pharmaceuticals Inc RAD for use in a method to treat mutant estrogen receptor positive breast cancer or mutant estrogen receptor positive ovarian cancer
RU2769527C2 (ru) 2016-06-22 2022-04-01 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
KR102322802B1 (ko) 2017-01-05 2021-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
US11643385B2 (en) 2018-07-04 2023-05-09 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
EP0643981B1 (en) * 1993-09-22 2002-01-09 Hisamitsu Pharmaceutical Co., Inc. A matrix for iontophoreses

Also Published As

Publication number Publication date
JPH11505222A (ja) 1999-05-18
AU5816596A (en) 1996-11-29
DE19517430A1 (de) 1996-11-14
IL118202A0 (en) 1996-09-12
WO1996035447A1 (en) 1996-11-14
EP0825872A1 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
CA2329005A1 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
DK583789D0 (da) System til transmucosal indgivelse af den aktive bestanddel af et laegemiddel
EP0727217A3 (en) Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient
EP1468679A3 (en) Controlled release formulation containing tramadol
HUT60466A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
KR970006279A (ko) 약제학적 활성 성분으로서의 6-디메틸아미노메틸-1-페닐-사이클로헥산 화합물
EP0645136A3 (en) Pharmaceutical preparation of the type: physiologically active substance with sustained release.
HUT59314A (en) Process for producing pharmaceutical composition comprising minocylcine active ingredient and suitable for a single daily administration
HK1001860A1 (en) I-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
HUT64065A (en) Process for producing quinolone- and naphthyridonecarboxylic acid derivatives and pharmaceutical compositions comprising same as active ingredient
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
IL106326A (en) Analogs of parathyroid hormone, their production and pharmaceutical compositions containing them
ZA968715B (en) Stable pharmaceutical forms of administration containing parathyroid hormone.
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
IL70071A (en) Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
HUT49625A (en) Process for producing macrolid compounds and pharmaceutical compositions comprising such active ingredient
ZA963714B (en) Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours.
PL332249A1 (en) Pharmaceutical microspheres of varproinic acid for oral administration
NZ244320A (en) Acylals of imidazole-5-carboxylic acid, preparation and pharmaceutical compositions thereof
IL126892A0 (en) Pharmaceutical compositions for the sustained release of insoluble active principles
HUT75029A (en) Systems for controlled release of pilocarpine, and semipermeable capsule containing the active ingredient
AU2080695A (en) Pharmaceutical inhalation compositions containing a solid active ingredient
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
HUT47127A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions comprising such active ingredient